BPC-157 / TB-500 peptides

Estimated longevity benefit: +0.8 years. Evidence score: 68/100.

Overview

BPC-157 and TB-500 are regenerative peptides that promote tissue repair, angiogenesis, and the reduction of systemic inflammation. By accelerating the healing of musculoskeletal injuries and supporting gut barrier integrity, they help maintain the consistent physical activity levels required for long-term healthspan.

Evidence assessment

BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protein found in human gastric juice. In animal studies, it has demonstrated remarkable healing effects across multiple tissue types — tendons, ligaments, muscles, nerves, and the GI tract. A 2018 review by Sikiric et al. documented BPC-157's ability to accelerate tendon-to-bone healing, promote angiogenesis, and modulate nitric oxide pathways. TB-500 (Thymosin Beta-4) is a naturally occurring peptide involved in wound healing and cell migration, with research showing accelerated tissue repair and reduced inflammation in animal models. The longevity connection is indirect but meaningful: faster injury recovery means more consistent exercise adherence, which is the single most impactful longevity intervention. However, no human randomized controlled trials exist for either peptide. The FDA has issued warnings about unregulated peptide sales, and quality control is a significant concern. These remain experimental compounds with promising preclinical data but unproven human efficacy and safety profiles. The mechanism of BPC-157 involves the upregulation of growth factor receptors and the promotion of blood vessel formation in damaged tissues. TB-500 complements this by increasing the flexibility of the cellular cytoskeleton, allowing for faster migration of repair cells to the site of injury. While anecdotal evidence in the biohacking community is vast, users must weigh the potential for rapid healing against the lack of long-term safety data in humans.

Implementation protocol

Critical Disclaimer: Peptide therapy remains an experimental field with significant regulatory and safety uncertainties that must be carefully considered. Because these compounds have not undergone the rigorous clinical testing required for standard pharmaceuticals, their long-term effects on human health are not yet fully understood. - No human randomized controlled trials (RCTs) exist for BPC-157 or TB-500 - Regulatory status varies significantly by country — in the US, FDA has issued warnings about unregulated peptide products - Quality and purity of commercially available products is highly uncertain - This information is for educational purposes only — not a recommendation to use - The evidence is overwhelmingly preclinical (animal studies and in vitro) — human safety and efficacy are unproven - Only pursue under the guidance of a physician experienced in peptide therapy

BPC-157 Protocol (Anecdotal/Preclinical — No Human RCTs): BPC-157 is often used to target localized inflammation and accelerate the healing of the gastric lining or musculoskeletal tissues. The choice of administration route often depends on the specific therapeutic goal, with oral forms being preferred for digestive health and localized injections for joint or muscle recovery. - Oral capsules: 250-500mcg daily — most accessible route, may be effective for gut-related issues - Sublingual: 250-500mcg under tongue — faster absorption than oral capsules - Injectable (requires medical supervision): 250-500mcg subcutaneous injection near the injury site - Typical cycle: 4-8 weeks for injury recovery, then discontinue and assess - Some practitioners use 2-4 week cycles with 2-week breaks between - Most commonly used for: gut healing (IBS, leaky gut), tendon/ligament injuries, joint pain, muscle tears - Oral route may be preferred for GI issues; injection may be preferred for localized musculoskeletal injuries - Take on an empty stomach for better absorption (both oral and sublingual) - Some practitioners split the daily dose into 2 administrations (morning and evening) for sustained levels

TB-500 Protocol (Anecdotal/Preclinical — No Human RCTs): TB-500 is typically administered systemically to support overall tissue remodeling and the migration of repair cells throughout the body. Its longer half-life compared to other peptides allows for a less frequent dosing schedule, often involving an intensive loading phase followed by a maintenance period. - Loading phase: 2-5mg twice weekly via subcutaneous injection for 4-6 weeks - Maintenance phase: 2-5mg every 2 weeks after loading (if continued) - Injectable form is the most commonly used and most studied in animal models - Oral/sublingual TB-500 availability is increasing but absorption data is limited - Total loading phase exposure: 16-60mg over 4-6 weeks (significant peptide volume) - Often used for: muscle/connective tissue recovery, systemic healing, reducing scar tissue - Some users report improved hair growth and skin healing (anecdotal) - TB-500 is naturally produced by the thymus gland and involved in wound healing and cell migration

Combination Use (BPC-157 + TB-500): Combining these two peptides is a common strategy intended to leverage their distinct but complementary mechanisms for maximum regenerative potential. While this approach is theoretically sound based on animal models, it significantly increases the complexity and cost of the intervention. - Some practitioners combine both peptides for synergistic healing effects - Rationale: BPC-157 targets local tissue repair and angiogenesis; TB-500 promotes systemic cell migration and tissue remodeling - Typical combination: BPC-157 250-500mcg daily + TB-500 2-5mg twice weekly during loading - The combination is theoretically synergistic but has not been studied together in any clinical setting - Cost consideration: Combined protocols can cost $200-500+ per month depending on source and dosing

Beginner Approach (If Pursuing Under Medical Guidance): A cautious introduction to peptide therapy involves starting with a single agent and a low-risk administration route to establish baseline tolerability. This step-by-step method is essential for identifying potential side effects before advancing to more complex or invasive protocols. - Start with oral BPC-157 only (250mcg daily) — lowest risk route of administration - Try for 2-4 weeks to assess tolerability and any noticeable effects - Track symptoms daily: joint pain levels, gut symptoms, energy, recovery from exercise - If pursuing for a specific injury, document the injury status with photographs or functional tests before starting - Do not combine multiple peptides initially — establish tolerability with one compound first - Only consider injectable protocols under direct physician supervision

Monitoring and Tracking: Objective documentation of your symptoms and functional capacity is the only way to evaluate the effectiveness of an experimental peptide protocol. Because there are no standard biomarkers for peptide efficacy, you must rely on meticulous personal records and regular medical check-ups. - Before starting: Document the specific condition you are targeting (injury location, gut symptoms, etc.) - Use standardized pain scales (1-10) to track changes daily - For injuries: Measure range of motion, strength, and functional ability before and during protocol - For gut healing: Track symptoms using a food/symptom diary - Blood work: Get baseline CBC, metabolic panel, liver enzymes — repeat after completing a cycle - No established biomarkers exist to measure BPC-157 or TB-500 effectiveness objectively - Progress photos for visible injuries (bruising, swelling, scar tissue)

Timeline of Expected Effects (Based on Anecdotal Reports — Not Clinical Evidence): The timeline for peptide-assisted healing is highly variable, with some users reporting rapid pain relief and others requiring several weeks of consistent use. Understanding the anecdotal stages of recovery helps set realistic expectations for what is essentially an unproven medical intervention. - Day 1-7: Some users report reduced inflammation and pain at injury sites - Week 1-2: Potential improvement in gut symptoms (if targeting GI issues) - Week 2-4: Accelerated tissue healing may become noticeable — improved range of motion, reduced pain - Week 4-8: Maximum benefit typically reported during this window for injury recovery - Post-cycle: Some users report sustained improvements after discontinuation; others find benefits fade - Not a chronic therapy — typically used in defined cycles for specific healing goals

Common Mistakes: The most frequent pitfalls in peptide use involve sourcing products from unreliable vendors and neglecting the foundational rehabilitation work required for true healing. Peptides should be viewed as a potential adjunct to, rather than a replacement for, standard medical care and physical therapy. - Purchasing from unverified sources without third-party testing — quality varies enormously - Self-injecting without proper sterile technique — infection risk is real - Using peptides as a substitute for proper rehabilitation (physical therapy, rest, progressive loading) - Expecting peptides to heal structural damage that requires surgical intervention - Combining multiple experimental compounds simultaneously — impossible to assess what is working - Not tracking symptoms objectively — relying on subjective "feel" without documentation - Continuing use indefinitely without defined goals or stopping criteria

Quality Concerns (Critical): The lack of regulatory oversight in the peptide market makes the verification of purity and concentration the responsibility of the consumer and their physician. Only products with transparent, independent laboratory testing should be considered to minimize the risk of contamination or incorrect dosing. - Source from reputable peptide suppliers with established track records - Demand third-party purity testing: HPLC (High-Performance Liquid Chromatography) and mass spectrometry - Certificate of Analysis (CoA) should be available and ideally from an independent lab, not the manufacturer - Avoid products with proprietary blends, vague labeling, or undisclosed ingredients - Pharmaceutical-grade peptides from compounding pharmacies are the safest option (require prescription) - Research-grade peptides sold online are NOT manufactured to pharmaceutical standards - Storage: Most peptides require refrigeration after reconstitution; follow specific storage instructions

Safety and Caution: The long-term safety of synthetic peptides in humans is unknown, making it imperative to use these substances only under professional guidance and with a clear exit strategy. Any adverse reactions should be taken seriously and reported to your healthcare provider immediately to prevent lasting harm. - Long-term safety data does not exist for either BPC-157 or TB-500 in humans - Potential for unknown drug interactions — inform all healthcare providers - Not FDA-approved for any human indication - Self-injection carries infection risk: use sterile technique, alcohol swabs, single-use needles - Theoretical concern: BPC-157 may promote angiogenesis (blood vessel growth) — this could theoretically be problematic in individuals with existing tumors (not studied, but a valid safety question) - Stop immediately if you experience unusual swelling, redness at injection sites, fever, or allergic symptoms - Not studied in pregnancy, breastfeeding, or children — avoid in these populations - Consult with a physician experienced in peptide therapy before starting any protocol

Scientific citations

Expert perspectives

Related interventions